AU
UK
CA
US
IND
NZ
Last update at 2026-06-03T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
Thu 15 May 25, 08:20 PMSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
Wed 12 Mar 25, 09:08 PM3 Stocks Under $10 With the Potential for Massive Gains
Mon 22 Jul 24, 12:00 AM3 Dirt-Cheap Drug Developers With Blockbuster Potential
Thu 11 Jul 24, 11:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -67.50900M | -35.95400M | -58.33300M | -53.71000M | -19.20400M |
| Minority interest | - | - | - | - | - |
| Net income | -62.80900M | -32.86600M | -55.18500M | -55.23400M | -12.46800M |
| Selling general administrative | 62.96M | 49.92M | 14.63M | 10.65M | 8.68M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 4.46M | 12.85M | - | 0.12M | 0.26M |
| Reconciled depreciation | 0.61M | 0.38M | 0.11M | 0.11M | 0.05M |
| Ebit | -85.75700M | -60.82500M | -51.14900M | -48.92100M | -29.01600M |
| Ebitda | -85.32200M | -61.72500M | -52.31800M | -48.63800M | -28.96300M |
| Depreciation and amortization | 0.43M | -0.90000M | -1.16900M | 0.28M | 0.05M |
| Non operating income net other | - | 27.54M | -6.00300M | -3.80300M | 12.40M |
| Operating income | -85.75700M | -60.82500M | -51.14900M | -48.92100M | -29.98300M |
| Other operating expenses | 90.85M | 73.99M | 50.81M | 49.04M | 30.24M |
| Interest expense | 5.20M | 2.66M | 1.18M | 0.99M | 2.05M |
| Tax provision | -4.70000M | -3.08800M | -3.14800M | 0.00000M | -6.73600M |
| Interest income | 1.42M | 0.02M | 0.19M | 0.81M | 0.97M |
| Net interest income | -5.37200M | -3.93900M | -2.19300M | -1.35200M | -1.08700M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -4.70000M | -3.08800M | -3.14800M | 1.52M | -6.73600M |
| Total revenue | 5.09M | 13.16M | 0.00000M | 0.12M | 0.26M |
| Total operating expenses | 90.22M | 73.68M | 50.81M | 49.04M | 30.24M |
| Cost of revenue | 0.63M | 0.31M | - | - | 0.00000M |
| Total other income expense net | 18.25M | 24.87M | -7.18400M | -4.78900M | 11.87M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -62.80900M | -32.86600M | -55.18500M | -53.71000M | -12.46800M |
| Net income applicable to common shares | - | -32.86600M | -55.18500M | -53.71000M | -12.46800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 128.41M | 87.81M | 119.84M | 102.54M | 57.15M |
| Intangible assets | - | 0.41M | 1.06M | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 5.55M | 0.06M | 0.00400M | 0.37M | 0.67M |
| Total liab | 55.45M | 84.58M | 78.58M | 79.78M | 44.26M |
| Total stockholder equity | 72.96M | 3.23M | 41.26M | 22.76M | 12.89M |
| Deferred long term liab | - | - | 0.15M | 0.19M | 0.07M |
| Other current liab | 7.62M | 11.40M | 5.70M | 17.56M | 3.80M |
| Common stock | 0.04M | 0.04M | 0.03M | 0.02M | 0.10M |
| Capital stock | 0.04M | 0.04M | 0.03M | 0.02M | 0.10M |
| Retained earnings | -355.24700M | -422.28800M | -359.47900M | -326.61300M | -271.42800M |
| Other liab | - | - | 21.41M | 33.59M | 21.60M |
| Good will | - | - | - | - | - |
| Other assets | - | - | 7.66M | 4.03M | 1.16M |
| Cash | 34.43M | 45.81M | 104.48M | 93.04M | 41.92M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 16.30M | 17.62M | 13.62M | 26.40M | 11.01M |
| Current deferred revenue | 1.19M | - | - | 4.14M | - |
| Net debt | -19.35000M | 2.78M | -60.85800M | -73.19900M | -27.03600M |
| Short term debt | 0.34M | 0.28M | 0.07M | 0.05M | 0.04M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 15.08M | 48.60M | 43.63M | 19.84M | 14.88M |
| Other stockholder equity | 428.17M | 425.49M | 400.70M | 349.35M | 284.23M |
| Property plant equipment | - | - | 0.11M | 3.30M | 0.41M |
| Total current assets | 102.12M | 79.06M | 109.38M | 98.21M | 52.40M |
| Long term investments | 23.59M | - | - | - | - |
| Net tangible assets | - | - | 40.20M | 22.76M | 12.89M |
| Short term investments | 40.31M | 27.69M | - | 0.00000M | 6.49M |
| Net receivables | 21.83M | 2.10M | 0.86M | 2.88M | - |
| Long term debt | 12.16M | 45.39M | 28.75M | 16.52M | 11.52M |
| Inventory | 0.00000M | 0.90M | 0.46M | 1.92M | - |
| Accounts payable | 7.15M | 5.94M | 7.85M | 4.64M | 7.18M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | -0.17200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.03M | 0.02M | 0.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -359.47900M | -326.61300M | -271.42800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.17M | 5.75M | 6.49M | 1.03M | 1.16M |
| Deferred long term asset charges | - | - | 0.15M | 0.19M | 0.07M |
| Non current assets total | 26.30M | 8.75M | 10.46M | 4.33M | 4.75M |
| Capital lease obligations | 2.92M | 3.20M | 3.27M | 3.33M | 3.36M |
| Long term debt total | - | - | 28.75M | - | 11.52M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -27.38900M | -1.17200M | 6.47M | 26.24M | -0.23800M |
| Change to liabilities | - | 7.70M | -2.29600M | 5.09M | -0.03400M |
| Total cashflows from investing activities | - | -1.17200M | 6.47M | 26.24M | -0.80300M |
| Net borrowings | - | 28.75M | 10.00M | -1.22600M | -2.27200M |
| Total cash from financing activities | 48.60M | 67.12M | 94.00M | 42.30M | 29.42M |
| Change to operating activities | - | 6.54M | -0.92200M | 3.25M | -6.36700M |
| Net income | -62.80900M | -32.86600M | -55.18500M | -53.71000M | -12.46800M |
| Change in cash | -58.67000M | 11.39M | 51.12M | 30.43M | 0.30M |
| Begin period cash flow | 104.70M | 93.31M | 42.19M | 11.77M | 11.47M |
| End period cash flow | 46.03M | 104.70M | 93.31M | 42.19M | 11.77M |
| Total cash from operating activities | -79.88300M | -54.56000M | -49.35400M | -38.11900M | -28.32300M |
| Issuance of capital stock | 47.25M | 38.56M | 90.55M | 46.34M | 31.66M |
| Depreciation | 0.61M | 0.38M | 0.11M | 0.11M | 0.05M |
| Other cashflows from investing activities | - | -1.17200M | - | 26.24M | -0.23800M |
| Dividends paid | - | - | -10.02800M | - | - |
| Change to inventory | -0.43600M | -5.29200M | -5.29200M | -5.29200M | -5.29200M |
| Change to account receivables | -1.24000M | -0.86100M | -0.86100M | -0.86100M | -0.86100M |
| Sale purchase of stock | - | 38.57M | -0.20800M | 46.39M | 31.70M |
| Other cashflows from financing activities | 1.38M | 29.82M | 14.18M | 13.19M | -2.23300M |
| Change to netincome | - | -26.72200M | 7.74M | 5.80M | -10.05000M |
| Capital expenditures | 0.00900M | 1.17M | 0.00400M | 0.00400M | 0.56M |
| Change receivables | - | -0.86100M | - | - | - |
| Cash flows other operating | - | 1.79M | -0.12800M | 3.43M | -6.14100M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 11.39M | 51.12M | 30.43M | 0.30M |
| Change in working capital | 0.76M | 3.15M | -3.21800M | 8.35M | -6.40100M |
| Stock based compensation | 3.69M | 2.09M | 2.22M | 1.83M | 1.82M |
| Other non cash items | -22.13000M | 1.50M | 2.00M | 1.34M | 0.42M |
| Free cash flow | -79.89200M | -55.73200M | -49.35800M | -38.11900M | -28.88800M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SCYX Scynexis Inc |
-0.43 8.43% | 4.67 | 1.11 | 2.25 | 0.39 | 0.75 | 0.0076 | -0.0667 |
| ZTS Zoetis Inc |
1.20 1.57% | 77.59 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.58 1.91% | 31.01 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 153.91 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| GALDY GALDERMA GROUP AG |
-0.79 1.89% | 40.92 | 74.21 | 41.67 | 8.64 | 5.55 | 9.15 | 42.22 |
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
| Name | Title | Year Born |
|---|---|---|
| Dr. Marco Taglietti M.D. | CEO, Pres & Director | 1960 |
| Mr. David Gonzalez Angulo M.D. | Chief Medical Officer | 1965 |
| Mr. Ivor Macleod CPA, M.B.A. | Chief Financial Officer | 1962 |
| Mr. Scott Sukenick J.D. | Gen. Counsel & Corp. Sec. | 1978 |
| Debbie Etchison | Exec. Director of Communications | NA |
| Mr. David Gonzalez Angulo M.D. | CEO, President & Director | 1965 |
| Mr. Scott Sukenick J.D. | Chief Legal Officer & Corporate Secretary | 1978 |
| Mr. Ivor Macleod CPA, M.B.A. | Chief Financial Officer | 1961 |
| Debbie Etchison | Executive Director of Communications | NA |
| Ms. Daniella Gigante | Vice President of Human Resources & Information Technology | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...